XTalks

FEBRUARY 5, 2024

It is prescribed for the treatment of metastatic breast cancer in patients with HR-positive/HER2-negative status. Novartis attributed the growth to increased recognition of the drug’s life-extension benefit in metastatic breast cancer. Price of Verzenio: The list price of Verzenio is $15,405.72 For Kisqali, sales reached $1.5

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

FEBRUARY 5, 2024

It is prescribed for the treatment of metastatic breast cancer in patients with HR-positive/HER2-negative status. Novartis attributed the growth to increased recognition of the drug’s life-extension benefit in metastatic breast cancer. Price of Verzenio: The list price of Verzenio is $15,405.72 For Kisqali, sales reached $1.5

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 4, 2021

announced that the EMA has validated for review the MAA for somatrogon, a long-acting recombinant human growth hormone intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency. Somatrogon — In February 2021, Pfizer and OPKO Health Inc.

Vaccination 40

Vaccination Vaccine Production Sales 40